Polycystic ovarian syndrome (PCOS) and thyroid disorders are the two most common hormonal problems that women experiencing their reproductive years may experience; however, it appears that these two conditions are often misidentified or mixed up. Both disorders can adversely affect menstrual cycle regulation, contributing to excessive weight gain, causing fatigue, making it difficult to get pregnant, and producing many of the same symptoms.
There is a higher percentage of thyroid autoimmunity and dysfunction among women who have been diagnosed with PCOS than among women without PCOS, which causes the ovaries to appear similar to PCOS on ultrasound as a result of changes in ovarian structure.
Table of Contents
ToggleDifferentiation Framework: A Step-by-Step Clinical Approach
| Diagnostic step | What To Do | Why it Matters |
| 1 step – Exclude thyroid first | Measure TSH, Free T4, Free T3, and TPO antibodies | PCOS is a diagnosis of exclusion; thyroid disorder must be ruled out first |
| 2 step – Assess Androgens | Check free testosterone, DHEA-S, SHBG, free androgen index | Elevated androgens point to PCOS; thyroid disorders do not typically raise them. |
| 3-step – Evaluate Ovarian Function | Measure LH, FSH, AMH; pelvic ultrasound | Polycystic ovary morphology + elevated AMH are hallmarks of PCOS, not thyroid disease. |
| 4-step – Screen for Insulin Resistance | Fasting insulin, HOMA-IR, HbA1c, Fasting glucose | 70 % of PCOS patients are insulin resistant; uncommon as a primary thyroid feature |
| 5 step – Apply Rotterdam Criteria | Confirm ≥ 2 of 3: oligo-anovulation, hyperandrogenism, polycystic ovaries | A formal PCOS diagnosis requires meeting Rotterdam criteria after thyroid is excluded |
| 6 step – check for Co-existence | If symptoms persist post-thyroid treatment, reassess the PCOS panel | Up to 50 % of PCOS patients may have concurrent thyroid pathology |
Elevated TSH in primary hypothyroidism increases thyrotropin-releasing hormone (TRH), which in turn stimulates prolactin secretion. The rise in prolactin levels can lead to disruption of the LH: FSH ratio, anovulation, and cystic changes on ultrasound of the ovaries that resemble polycystic ovarian syndrome (PCOS). However, these changes may resolve after treatment of hypothyroidism.
Side-by-Side Symptom Comparison
There are many similarities between the symptom profiles of thyroid disorders (hypothyroidism unless otherwise stated) and PCOS. However, their combinations and the accompanying symptoms are often helpful in distinguishing between the two conditions.
| Symptom/feature | Thyroid Disorders | PCOS |
| Menstrual irregularity | Light, irregular, or absent periods (hypo); lighter or heavier cycles; anovulation | Oligomenorrhea or amenorrhea due to androgen excess & anovulation |
| Weight changes | Weight gain with fatigue (hypo);
unexplained weight loss (hyper) |
Gradual weight gain; central obesity; linked to insulin resistance |
| Fatigue | Profound, constant exhaustion regardless of activity level | Fatigue is present but often linked to sleep disruption or metabolic load |
| Hair changes | Diffuse hair thinning across scalp; outer eyebrow loss (hypo) | Scalp hair thinning (androgenic alopecia) + unwanted facial/body hair |
| Skin | Dry, coarse, thickened skin; puffy face (hypo);
thin, moist skin (hyper) |
Acne (jaw/chin); oily skin; acanthosis nigricans (dark neck patches) |
| Mood & cognition | Depression, brain fog, memory issues (hypo);
Anxiety, irritability (hyper) |
Anxiety, depression;
elevated cortisol reactivity |
| Heart rate | Slow pulse, bradycardia (hypo);
Fast pulse, palpitations (hyper) |
Typically normal; may be elevated if obese |
| Cold/heat intolerance | Cold intolerance (hypo);
Heat intolerance and sweating (hyper) |
Generally not present as a cardinal obese |
| Fertility impact | Anovulation; miscarriage risk elevated; thyroid autoimmunity raises risk | Primary cause of anovulatory infertility in reproductive-age women |
| Hirsutism/virilisation | Absent or mild | Common, driven by elevated androgens (testosterone, DHEA-S) |
| Goitre/neck changes | May present as an enlarged thyroid gland | Not applicable |
| Metabolic risk | Dyslipidemia (hypo);
Cardiovascular risk (hyper) |
Insulin resistance, pre-diabetes, metabolic syndrome, dyslipidemia |
Which Blood Tests distinguish them?
No single test alone determines whether a person has either of the diseases described above. The value of using a diagnostic protocol which evaluates the overall laboratory pattern across a comprehensive panel of tests. Below is a table of the major laboratory markers of the diseases mentioned above.
| Test | Role | In Thyroid Disorder | In PCOS |
| TSH | Pituitary signal to thyroid | High in hypothyroidism;
Low in hyperthyroidism |
Normal (unless co-existing thyroid disease) |
| Free T4/ Free T3 | Active thyroid hormones | Low in hypothyroidism;
High in hyperthyroidism |
Normal |
| LH/FSH ratio | Gonadotropin balance | May be disturbed secondarily in hypothyroidism | LH: FSH ratio often > 2:1 or 3.1 |
| Total & Free Testosterone | Androgen level | Normal or slightly altered | Elevated; key diagnostic markers |
| DHEA-S | Adrenal androgen | Normal | Often elevated |
| AMH | Ovarian follicle reserve | Normal | Significantly elevated (3-5× normal) |
| Fasting insulin/HOMA-IR | Insulin resistance | Normal unless metabolically affected | Elevated in 70 % of PCOS pateints |
| Prolactin | Pituitary hormone | Elevated in primary hypothyroidism (TRH cross-stimulation) | Usually normal; checked to rule out other causes |
| HbA1c/Fasting Glucose | Glycaemic status | May worsen with hypothyroidism | Elevated with insulin resistance |
| Lipid Panel | Cardiovascular risk | LDL increases, HDL decreases in hypothyroidism | Dyslipidemia common |
Can you have both simultaneously?
Women with PCOS have a 22-50% prevalence of thyroid disorders, including subclinical and overt hypothyroidism, positive TPO antibodies, and goitre. They often show increased rates of Hashimoto’s thyroiditis and high anti-thyroid antibodies due to immune dysregulation. Altered estrogen/androgen ratios predispose them to autoimmune thyroid diseases.
Insulin resistance, present in up to 70% of women with PCOS, disrupts the conversion of T4 to T3, leading to higher reverse T3 levels. Higher TSH levels correlate with increased BMI, worsened insulin resistance, and elevated testosterone. While hypothyroidism doesn’t cause PCOS, both conditions share risks from immune dysregulation and obesity.
Treatment Differences
Treatment strategies for the two conditions are distinct in mechanisms but may need careful coordination when both are present.
| Treatment Domain | Thyroid disorders | PCOS |
| First-line Medication | Levothryroxine (synthetic T4), taken daily on an empty stomach (hypothyroidism); antithyroid drugs or RAI (hyperthyroidism) | Oral contraceptives (regulate cycle, suppress androgens; metformin (insulin sensitiser) |
| Fertility Treatment | Levothyroxine started ≥ months before conception; TSH target < 2.5 mIU/L in pregnancy | Clomiphene/letrozole for ovulation induction; metformin improves ovulation rates |
| Androgen Management | Not applicable | Combined OCPs; anti-androgens (spironolactone); topical treatments for hirsutism |
| Metabolic/weight | Thyroid hormone normalisation often corrects weight and dyslipidemia | Low-GI diet, calorie deficit, exercise; GLP-1 agonists (e.g., semaglutide) for obesity |
| Lifestyle Guidance | Consistent medication adherence; avoid calcium/iron dose; monitor TSH 6-monthly | Exercise improves insulin sensitivity; a low-carb or Mediterranean diet; and sleep hygiene |
| Monitoring | TSH, free T4 every 6-12 months once stable; antibodies if autoimmune suspected | Androgens, lipids, fasting insulin, HbA1c annually; pelvic ultrasound as needed |
| If both present | Treat thyroid first; re-evaluate PCOS symptoms 3-6 months after TSH normalisation | Adjust the levothyroxine dose; metformin may lower TSH levels, requiring dose review. |
Frequently Asked Questions
While thyroid disorders do not directly cause PCOS, they can produce PCOS-like symptoms such as irregular periods, weight gain, and ovulatory dysfunction. Additionally, hypothyroidism may exacerbate the hormonal and metabolic imbalances associated with PCOS.
Yes. Women with PCOS should have their thyroid function assessed to identify any underlying thyroid disorders. Thyroid conditions commonly coexist with PCOS and can affect fertility, metabolism, and menstrual regularity. Testing TSH and other thyroid hormones is an important part of a comprehensive evaluation.
Treating thyroid dysfunction may improve menstrual regularity, ovulation, metabolic health, and fertility outcomes in women with PCOS. However, thyroid treatment alone will not fully address PCOS, which typically requires a broader management approach involving lifestyle changes, hormonal regulation, and metabolic support.
Yes. Women with both thyroid dysfunction and PCOS can achieve healthy pregnancies with appropriate planning and medical supervision. PCOS is associated with an increased risk of miscarriage, gestational diabetes, preeclampsia, and preterm birth, while uncontrolled thyroid disorders may further increase these risks. Optimising thyroid hormone levels, particularly TSH, before conception is essential. Consult your doctor before trying to conceive to ensure both conditions are well managed.
Yes. Both PCOS and hypothyroidism can significantly affect mood and mental wellbeing, contributing to symptoms such as anxiety, depression, irritability, and mood fluctuations. In hypothyroidism, these effects are linked to slowed neurological function, while in PCOS they are often related to hormonal imbalances, insulin resistance, and the emotional impact of managing a chronic condition. An undiagnosed thyroid disorder may worsen mental health symptoms in women with PCOS, so discussing these concerns with your doctor is important.
References:
- Khashchenko, E., Uvarova, E., Vysokikh, M., Ivanets, T., Krechetova, L., Tarasova, N., Sukhanova, I., Mamedova, F., Borovikov, P., Balashov, I., & Sukhikh, G. (2020). The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. Journal of Clinical Medicine, 9(6), 1831.
- Krysiak, R., Kowalcze, K., Ott, J., Burgio, S., Zaami, S., & Okopień, B. (2025). Polycystic Ovary Syndrome Attenuates TSH-Lowering Effect of Metformin in Young Women with Subclinical Hypothyroidism. Pharmaceuticals, 18(8), 1149.
- Palomba, S., Colombo, C., Busnelli, A., Caserta, D., & Vitale, G. (2023). Polycystic ovary syndrome and thyroid disorder: A comprehensive narrative review of the literature. Frontiers in Endocrinology, 14, 1251866.
- Rashidi, B. H., Gorginzadeh, M., Aalipour, S., & Sills, E. S. (2016). Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: Descriptive data from a university based infertility center. Archives of Endocrinology and Metabolism, 60(5), 486–491.
- Sharma, J., Mahat, B., Tiwari, S., Singh, N. K., Yadav, R., & Thapa, D. (2024). Thyroid Disorders in Patients with Polycystic Ovarian Syndrome in a Tertiary Care Center: An Observational study. JNMA: Journal of the Nepal Medical Association, 62(280), 819–822.
- Singla, R., Gupta, Y., Khemani, M., & Aggarwal, S. (2015). Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian Journal of Endocrinology and Metabolism, 19(1), 25–29.
Anna Haotanto is the Founder of Zora Health and a passionate advocate for women’s empowerment. Anna’s personal experiences with egg-freezing, PCOS, perimenopause and the challenges of fertility have fueled her mission to provide high-quality information, financing, and support to help women and couples navigate their fertility journeys with confidence. She is also recognised for her achievements in finance, entrepreneurship, and women’s empowerment, and has been featured in various media outlets. You can also follow her on Linkedin or Instagram.
